Q&A highlights: Cell manufacturing with GMP ancillary material solutions from BioLegend

Thank you to everyone who attended our webinar on 23 September 2025, ‘Cell manufacturing with GMP ancillary material solutions from BioLegend‘. Due to time constraints during the live event, we weren’t able to address all of the valuable questions from our audience. To ensure you receive the comprehensive answers you deserve, we’ve compiled written responses from Kenta Yamamoto to the questions we didn’t have the opportunity to cover during the webinar.

We hope this is a useful resource and thank those who submitted these thoughtful questions.

For smaller biotech companies just starting their cell therapy programs, what’s typically the most cost-effective entry point into your services?

All our services are planned through consultation and aligned with customer priorities, including timeline and budget. Typically, an ancillary material production project begins with small-scale feasibility runs, allowing customers to perform a “taste test” in a pre-clinical R&D setting to confirm the material meets their needs—without the significant upfront investment required for full-scale GMP production. This approach reinforces that it’s never too early to start and provides a cost-effective entry point into our services.

When implementing new procedures as customer needs evolve, what’s your typical validation timeline?

Timelines depend on the scope of the process being validated—both the physical aspects (e.g., labor intensity, use of new equipment, or similarity to existing processes) and the analytical procedures involved. In the past, we’ve completed several validations within weeks (such as protein purification or bioconjugation to new molecules). However, other processes, such as those requiring collaboration with external partners for validation, may take months.

When you’re working backwards from an IND submission date, how do you typically allocate time for unexpected regulatory feedback or additional testing requirements?

While there’s no set “buffer window” allocated, with projects that have a clear deadline or target date for an IND submission, we prioritize them to try and complete deliverables with as much time in advance, to give our customers enough time to gather all materials before their regulatory filings. The earlier we know about these timelines, the better we can plan ahead of time and operate towards completion.

When you implemented viral nanofiltration for the first time on GMP products, how did you validate this new process while maintaining timeline commitments?

With timeline and budget considerations in mind, we elected to perform the viral nanofiltration process validation in-house, focusing on analyzing protein yield and the biological performance of the antibody post-filtration to ensure consistent performance across multiple clones and antibody isotypes. We completed this validation within several weeks and subsequently incorporated it into our GMP antibody manufacturing process.

What ongoing support do you provide once a customer enters Phase I trials? Do you help with scaling for later phases?

When initiating a BP CDMS project for GMP material, we anticipate that as customers progress through clinical trials, they will require larger-scale ancillary material production beyond the initial phases. With this in mind, we plan projects—including legal and usage terms for certain reagents and clones, where applicable—with future scalability in mind to support routine clinical production.

For companies transitioning from academic research to commercial development, what’s the biggest mistake you see them make when it comes to ancillary material planning?

A common pitfall is not planning far enough ahead. It’s understandable, given that at the academic or early pre-clinical R&D stage the primary focus for the customer is on demonstrating proof of concept for a potential cell therapy product. This can most often be completed using readily available research- or analytical-grade reagents. Therefore, planning for clinical manufacturing most often becomes an afterthought. However, AM planning and production can take significant time. If left until the last minute, it can create major delays in project timelines.

We hope this webinar helps raise awareness and encourages prospective cell therapy manufacturers to start planning and sourcing AMs early, even during early development. Through our BP CDMS, we typically begin projects with non-GMP feasibility materials suitable for academic or pre-clinical R&D, regardless of whether they progress to full-scale GMP production later. It’s truly never too early to start consulting with potential AM partners.

Additionally, according to USP <1043>, the responsibility and risk management of AM use in manufacturing ultimately lie with the cell therapy manufacturer. Customers should define AM specifications and determine what is necessary and sufficient for qualification, rather than relying solely on suppliers for regulatory compliance. Therefore, “GMP-grade” reagents—especially across different AM suppliers—should not be viewed as a universal standard. Customers should fully understand how materials are manufactured and tested before committing to large-scale AM production or purchase.

You mentioned de novo recombinant antibody expression from customer sequences. How do you handle intellectual property concerns when customers provide proprietary sequences?

We work closely with customers to ensure proper data safeguarding and establish the necessary legal agreements between parties—such as Non-Disclosure Agreements (NDAs), Material Transfer Agreements (MTAs), or similar—to meet each customer’s compliance requirements before sharing any highly sensitive information, such as antibody sequences provided for expression in our facilities.

Beyond USP <1043>, are there other emerging guidelines or regulatory trends that companies should be aware of when planning their ancillary material strategy?

We work closely with customers to ensure proper data safeguarding and establish the necessary legal agreements between parties—such as Non-Disclosure Agreements (NDAs), Material Transfer Agreements (MTAs), or similar—to meet each customer’s compliance requirements before sharing any highly sensitive information, such as antibody sequences provided for expression in our facilities.

How do you stay current with evolving regulatory expectations, and how does that influence your service offerings?

A significant factor influencing how we evolve with changing regulatory expectations for AMs is through new customer inquiries and ongoing communication with our existing customers. As mentioned earlier regarding AM suitability and risk management, cell therapy manufacturers—our customers—are responsible for defining the AM specifications required for their intended use. Therefore, when new requirements arise, customers often have the most up-to-date information through their own regulatory teams or external consultants. We also attend bioprocessing and cell therapy-related conferences where attendees would also know and present on these topics to stay with up-to-date on the landscape.

Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of RegMedNet or Future Science Group.

In association with